An Open-label, Parallel-group Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cenerimod After Single-dose Administration in Subjects With Severe Renal Impairment and Control Subjects
Latest Information Update: 23 Aug 2023
At a glance
- Drugs Cenerimod (Primary)
- Indications Systemic lupus erythematosus
- Focus Pharmacokinetics
- Sponsors Idorsia Pharmaceuticals
- 17 Aug 2023 Status changed from active, no longer recruiting to completed.
- 19 Jun 2023 Planned End Date changed from 1 Sep 2023 to 10 Aug 2023.
- 19 Jun 2023 Planned primary completion date changed from 1 Sep 2023 to 27 Jul 2023.